Key Performance
More- Earnings Score: 46
- Momentum Score: 85
- True Yield: N/A
- Financial Health Score: 36
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The global Veterinary API Manufacturing Market is projected to grow from USD 7.21 billion in 2025 to USD 18.48 billion by 2035, driven by rising zoonotic disease prevention efforts, increasing pet ownership, and expanding animal healthcare investments. The market is segmented by service type, synthesis type, therapeutic category, and animal type, with North America and Asia-Pacific leading regional growth.
06/18/2026, 11:00 AM • GlobeNewswire
Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum
Elanco Animal Health (NYSE: ELAN) shares rose 9.33% following better-than-expected Q1 earnings of 40 cents per share (vs. 35 cents consensus) and $1.37 billion in sales (vs. $1.29 billion consensus). The company raised full-year guidance and reported strong growth across both Pet Health and Farm Animal segments, driven by new product launches and market expansion. Emergency use authorization approvals for Negasunt Powder and Tanidil also supported the stock movement.
05/06/2026, 2:33 PM • Benzinga
PRISM MarketView Launches PetCare Index
PRISM MarketView launched the PRISM PetCare Index to track publicly traded companies driving growth in the global pet care sector, projected to exceed $350 billion. The index includes companies advancing veterinary services, pet pharmaceuticals, insurance, diagnostics, and premium nutrition. Key companies highlighted include Elanco Animal Health, Chewy, and Trupanion, which are positioned to benefit from increasing consumer spending on pet healthcare, preventative services, and subscription-based offerings.
02/12/2026, 10:00 AM • GlobeNewswire
Should You Buy Zoetis Before Feb. 12?
Zoetis is set to report Q4 2025 earnings on Feb. 12 after disappointing guidance last quarter caused an 11% stock decline. While the company has beaten earnings in four consecutive quarters and lowered expectations could set up positive surprises, investors remain concerned about persistent macro headwinds affecting its livestock business and osteoarthritis treatments. The analyst recommends long-term investors wait until after earnings to enter a position, as further downside risk exists if guidance disappoints again.
02/09/2026, 8:15 AM • The Motley Fool
The global canine glucosamine supplement market is experiencing rapid growth, expanding from USD 236.44 million in 2025 to USD 257.55 million in 2026, with a projected CAGR of 7.27% through 2032, reaching USD 386.54 million. Market growth is driven by increased pet ownership, higher consumer spending on veterinary wellness, product innovation in formats like chewables and liquids, and omnichannel distribution strategies. Key opportunities include palatability improvements, multi-ingredient formulations, and age-specific product targeting.
01/19/2026, 5:49 AM • GlobeNewswire
The global canine vaccines market is projected to grow from USD 2.05 billion in 2025 to USD 3.45 billion by 2033, with a CAGR of 6.79%. Growth is driven by rising pet ownership, increased awareness of preventive animal healthcare, and higher veterinary spending. Core vaccines and rabies vaccines lead by market share, while combination vaccines and Lyme disease vaccines show the fastest growth. North America dominates with 36.5% market share, while Asia Pacific is expected to grow fastest at 8.22% CAGR.
01/16/2026, 11:00 AM • GlobeNewswire
The global diesel generator market is projected to grow at a CAGR of 5.28% from 2026 to 2032, reaching USD 27.42 billion by 2032 from USD 18.17 billion in 2024. Growth is driven by industrialization, infrastructure development, rising power outages, and data center expansion. However, the market faces headwinds from stringent environmental regulations, high operational costs, and the shift toward renewable energy solutions.
01/08/2026, 10:34 PM • GlobeNewswire
VIRBAC: Hyperthyroïdie féline : Virbac acquiert Thyronorm
Virbac has acquired a specialized liquid medication for feline hyperthyroidism from Norbrook for around £100 million. The product, currently generating €14 million in revenue, will be distributed under the Thyronorm and Felanorm brands across multiple markets.
12/16/2025, 3:53 AM • GlobeNewswire
VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm
Virbac has acquired an innovative drug from Norbrook to treat feline hyperthyroidism, valued at £100 million. The product will be distributed under Thyronorm and Felanorm brands across multiple countries, targeting a growing market of senior cats with this common endocrine disease.
12/16/2025, 3:53 AM • GlobeNewswire
Animal Health Focused Elanco Details Pipeline Momentum, US Investments, Cost-Saving Plans
Elanco Animal Health outlined a strategic plan for sustainable growth, focusing on innovation, portfolio expansion, and productivity. The company expects mid-single-digit organic revenue growth, increased R&D investments, and significant cost savings through its Ascend productivity initiative.
12/11/2025, 1:25 PM • Benzinga
Elanco Animal Health Stock Is Undervalued: Analyst
KeyBanc Capital Markets initiated coverage on Elanco Animal Health, rating it Overweight with a $27 price target. The analyst believes the company's innovative pet care products and improving financial metrics make the stock undervalued.
11/21/2025, 1:21 PM • Benzinga
The global companion animal health market is projected to grow from USD 25.28 billion in 2024 to USD 61.74 billion by 2034, driven by rising pet ownership, pet humanization trends, and advances in veterinary technologies.
10/31/2025, 10:00 AM • GlobeNewswire
Pet Cancer Therapeutics Market Size Worth USD 1,150.70 Million by 2034
The global pet cancer therapeutics market is projected to grow from $493 million in 2025 to $1.15 billion by 2034, driven by increasing pet cancer awareness, advanced veterinary treatments, and growing pet humanization trends.
10/22/2025, 2:58 AM • GlobeNewswire
The veterinary oncology market is projected to grow from $1.84 billion in 2025 to $3.55 billion by 2030, driven by technological advances, rising pet ownership, and increasing demand for advanced cancer treatments in veterinary medicine.
09/03/2025, 4:41 AM • GlobeNewswire
The global animal health market is projected to grow from $59.24 billion in 2024 to $110.16 billion by 2034, driven by rising pet ownership, demand for animal healthcare products, and increasing focus on animal welfare across commercial and companion animal sectors.
09/01/2025, 7:45 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.